期刊
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
卷 39, 期 8, 页码 1460-1468出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/0271678X19859847
关键词
Glioblastoma; blood-brain barrier; cerebral edema; dexamethasone; anti-vascular endothelial growth factor; Angiopoietin; Tie2; vascular endothelial protein tyrosine phosphatase
资金
- Else-Kroner Foundation Research College fellowship
- Clinical Translation Platform of the Frankfurt Cancer Institute
- German Consortium for Translational Cancer Research (DKTK), partner site Frankfurt/Mainz, Germany
- LOEWE Center for Personalized Translational Epilepsy Research (CePTER)
Glioblastoma is a highly aggressive and treatment resistant primary brain tumor. Features of glioblastoma include peritumoral cerebral edema, the major contributor to neurological impairment. Although the current clinical approach to edema management is administration of the synthetic corticoid dexamethasone, increasing evidence indicates numerous adverse effects of dexamethasone on glioblastoma burden at the molecular, cellular and clinical level. The contradictions of dexamethasone for glioblastoma and brain metastasis therapy are discussed in this article. Finally, alternative strategies for cerebrovascular edema therapy with vascular stabilizing, anti-permeability agents that are either approved or in clinical trials for diabetic retinopathy and macula edema, are addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据